SPRUCE BIOSCIENCES INCORPORATED (SPRB)

S&P 500 earnings roundup: big beats/misses from MSFT, AMZN, AAPL, META, QCOM, BA, XOM & more—plus next week’s key reports.

It beat on the two most important metrics in its second quarter.

SpaceX stock whipsawed through a volatile week, swinging from an all-time low to a sharp rebound and closing at a new low, as investors braced for the newly public company's first earnings report and a major share unlock.

To learn more about SPRB’s potential, visit the Spruce Biosciences, Inc. drug pipeline page. SpaceX or Tesla: One of Elon Musk’s Stocks Is a Buy, the Other a Mistake · A New Data Privacy Class-Action Lawsuit Sends Home Depot Stock (NYSE:HD) Sliding · Apple or Amazon: One Tech Stock Is a Buy Ahead of…

BlackRock reports beneficial ownership of 187,836 Spruce Biosciences shares, representing 6.8% of the common stock, with sole voting and dispositive power and no single client above 5%.